Specialty Hub

In-depth learning materials and relevant resources by areas of interest.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

In this section

Cardiology

Assorted resources on conditions connected to Cardiology.

Dermatology

Latest information on diseases in Dermatology.

Endocrinology

A detailed look at conditions connected to Endocrinology.

Gastroenterology and Hepatology

In-depth material on Gastroenterology and Hepatology.

Haematology

Assorted resources on conditions connected to Haematology.

Immunology

Immunology, the immune system and immune-mediated diseases.

Infectious Diseases

A detailed look at conditions connected to Infectious Diseases.

Neurology (CNS) and Pain

Learning materials and guidelines on Neurology (CNS) and Pain.

Oncology

A detailed look at conditions connected to Oncology.

Ophthalmology

Assorted resources on conditions connected to Ophthalmology.

Respiratory

In-depth material on Respiratory conditions.

Rheumatology

Latest information on diseases in Rheumatology.

Urology

Learning materials and guidelines on Urology.

Latest news

Drug news

Phase III AB09004 study of Masican shows efficacy and safety in mild-to-moderate Alzheimer’s disease.

AB Science announced that results from its Phase III AB09004 study of Masican (masitinib) on mild to moderate Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC) (July 26-30, 2021).

1 mins

Drug news

FDA approves Twyneo to treat acne vulgaris.

Sol-Gel Technologies, Ltd. announced that the FDA has approved its first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.

1 min

Drug news

ILLUMINATE-C phase III open-label study of Oxlumo shows efficacy in primary hyperoxaluria type 1.

Alnylam Pharmaceuticals announced positive topline results from the ILLUMINATE-C Phase III open-label study of Oxlumo (lumasiran) in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function.

1 min

See all news

You may be interested in...

Journal

Sleep Apnea and Chronic Kidney Disease: A State-of-the-Art Review

The objective of this review was to describe the epidemiology of sleep apnea in chronic kidney disease, understand the pathophysiological mechanisms by which OSA can lead to progression of chronic kidney disease, and consider the role of treatment with CPAP in this regard.

Journal

Beyond chronic kidney disease: the diagnosis of Renal Disease in the Elderly as an unmet need. A position paper endorsed by Italian Society of Nephrology (SIN) and Italian Society of Geriatrics and Gerontology (SIGG)

The dramatic increase in prevalence of chronic kidney disease (CKD) with ageing makes the recognition and correct referral of these patients of paramount relevance in order to implement interventions preventing or delaying the development of CKD complications and end-stage renal disease.

Journal

SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond

Chronic kidney disease (CKD) is a pressing public health concern. CKD attributed to diabetes, known as diabetic kidney disease (DKD), is the most common cause of kidney failure, accounting for half of all cases.